Prolonged shedding of pandemic influenza A (H1N1) 2009 virus in a pancreas-after-kidney transplant recipient

Journal of Clinical Virology

Volumn 61, Issue 2, 2014, Pages 302-304

  Bruminhent, Jackrapong ^a   Deziel, Paul J ^a   Wotton, Jason T ^b   Binnicker, Matthew J ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

^b MINNESOTA DEPARTMENT OF HEALTH   (United States)

Author keywords

Immunocompromised; Influenza; Oseltamivir; Shedding; Transmission; Transplant

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; OSELTAMIVIR; POSACONAZOLE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VORICONAZOLE; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRUS PROTEIN;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; CHILL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; EUROTIUM HERBARIORUM; FATIGUE; GENERAL CONDITION DETERIORATION; GLOMERULONEPHRITIS; GRAFT RECIPIENT; HISTOPATHOLOGY; HOSPITAL INFECTION; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLUENZA A (H1N1); INFLUENZA VIRUS A; KIDNEY TRANSPLANTATION; LUNG LAVAGE; LUNG MYCOSIS; LUNG NODULE; LYMPHOCYTOPENIA; MALE; MICROASCUS; MICROSPORIDIOSIS; MIDDLE AGED; MUTATION; NASOPHARYNGEAL ASPIRATION; PANCREAS TRANSPLANTATION; PANDEMIC INFLUENZA; PENICILLIUM; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; VIRAL CLEARANCE; VIRUS SHEDDING; GENETICS; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MISSENSE MUTATION; TIME; VIROLOGY;

DRUG RESISTANCE, VIRAL; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEURAMINIDASE; PANCREAS TRANSPLANTATION; TIME FACTORS; TRANSPLANT RECIPIENTS; VIRAL PROTEINS; VIRUS SHEDDING;

EID: 84924032784     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.07.004     Document Type: Article

References (21)

1. Kumar D., Michaels M.G., Morris M.I., Green M., Avery R.K., Liu C., et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010, 10(August (8)):521-526.
2. Calatayud L., Lackenby A., Reynolds A., McMenamin J., Phin N.F., Zambon M., et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg Infect Dis 2011, 17(October (10)):1807-1815.
3. Smud A., Nagel C.B., Madsen E., Rial Mdel C., Barcán L.A., Gomez A.A., et al. Pandemic influenza A/H1N1 virus infection in solid organ transplant recipients: a multicenter study. Transplantation 2010, 90(December (12)):1458-1462.
4. To K.K., Hung I.F., Li I.W., Lee K.L., Koo C.K., Yan W.W., et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010, 50(March (6)):850-859.
5. Meschi S., Selleri M., Lalle E., Bordi L., Valli M.B., Ferraro F., et al. Duration of viral shedding in hospitalized patients infected with pandemic H1N1. BMC Infect Dis 2011, 11:140.
6. Antón A A., López-Iglesias A.A., Tórtola T., Ruiz-Camps I., Abrisqueta P., Llopart L., et al. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. Diagn Microbiol Infect Dis 2010, 68(November (3)):214-219.
7. van der Vries E., Stittelaar K.J., van Amerongen G., Veldhuis Kroeze E.J., de Waal L., Fraaij P.L., et al. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog 2013, 9(May (5)):e1003343.
8. Weinstock D.M., Gubareva L.V., Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003, 348(February (9)):867-868.
9. Chen L.F., Dailey N.J., Rao A.K., Fleischauer A.T., Greenwald I., Deyde V.M., et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients - North Carolina, 2009. J Infect Dis 2011, 203(March (6)):838-846.
10. Herlocher M.L., Truscon R., Elias S., Yen H.L., Roberts N.A., Ohmit S.E., et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004, 190(November (9)):1627-1630.
11. Seto W.H., Cowling B.J., Lam H.S., Ching P.T., To M.L., Pittet D. Clinical and nonclinical health care workers faced a similar risk of acquiring 2009 pandemic H1N1 infection. Clin Infect Dis 2011, 53(August (3)):280-283.
12. Butler J., Hooper K.A., Petrie S., Lee R., Maurer-Stroh S., Reh L., et al. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1) pdm09 influenza viruses. PLoS Pathog 2014, 10(April (4).):1-3.
13. McCullers J.A. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006, 19(July (3)):571-582.
14. Gooskens J., Jonges M., Claas E.C., Meijer A., Kroes A.C. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009, 199(May (10)):1435-1441.
15. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008, 52(September (9)):3284-3292.
16. Renaud C., Boudreault A.A., Kuypers J., Lofy K.H., Corey L., Boeckh M.J., et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011, 17(April (4)):653-660. quiz 765.
17. Memoli M.J., Hrabal R.J., Hassantoufighi A., Eichelberger M.C., Taubenberger J.K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010, 50(May (9)):1252-1255.
18. Graitcer S.B., Gubareva L., Kamimoto L., Doshi S., Vandermeer M., Louie J., et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis 2011, 17(February (2)):255-257.
19. Whitley R.J., Boucher C.A., Lina B., Nguyen-Van-Tam J.S., Osterhaus A., Schutten M., et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis 2013, 56(May (9)):1197-1205.
20. Centers for Disease Control and Prevention Influenza Season Surveillance Summary. Available at: http://www.cdc.gov/flu/weekly/pdf/12-13%20Season%20Summary.pdf [accessed February 26] 2012-2013.
21. Sedyaningsih E.R., Malik M.S., Setiawaty V., Trihono T., Burhan E., Aditama T.Y., et al. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013, 346(May):1-6.